Cheaper eye drug could save millions in AMD treatment costs
NCT ID NCT03577041
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment offers the best value. The goal is to help healthcare systems choose the most cost-effective option without compromising patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab, Ranibizumab, Aflibercept (anti-VEGF drugs given as eye injections)
What this could lead to
If successful, this study could show that a cheaper drug (bevacizumab) works just as well as more expensive ones, potentially saving healthcare systems money while maintaining patient outcomes.
What could go wrong
This is an observational economic model, not a treatment trial. It won't test new drugs or prove which works best for individual patients. Results may not apply outside France.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.